Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
about
Cell cycle-specific function of Ikaros in human leukemiaPrognostification of ALL by CytogeneticsChildren's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaBET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.Association between CYP1A1 Ile462Val variation and acute leukemia risk: meta-analyses including 2164 cases and 4160 controlsRegulation of RAB5C is important for the growth inhibitory effects of MiR-509 in human precursor-B acute lymphoblastic leukemia.Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemiaIncreased μ-Calpain Activity in Blasts of Common B-Precursor Childhood Acute Lymphoblastic Leukemia Correlates with Their Lower Susceptibility to Apoptosis.A non-natural nucleoside with combined therapeutic and diagnostic activities against leukemiaAberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.The nursing dimension of providing palliative care to children and adolescents with cancerTransplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewConsiderations in the design of clinical trials for pediatric acute lymphoblastic leukemia.Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.Acute leukaemia: making sense of a complex blood cancer.MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL).The future role of monoclonal antibody therapy in childhood acute leukaemias.Predicting relapse risk in childhood acute lymphoblastic leukaemia.Naive tumour-specific CD4+ T cells were efficiently primed in acute lymphoblastic leukaemia.XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls.Whole-genome DNA methylation characteristics in pediatric precursor B cell acute lymphoblastic leukemia (BCP ALL).Signal-on electrochemical assay for label-free detection of TdT and BamHI activity based on grown DNA nanowire-templated copper nanoclusters.MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics InvestigatoAssociation between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study.
P2860
Q24298114-EA4D450E-71B0-41B7-86F6-F9FD8C27CA4BQ28087446-0A441C4C-C62B-4AAC-8ABB-BEDD3EEFD325Q33711119-61451283-B5AB-48A5-9789-947D67B3692CQ34033206-24A23E9D-2749-4D8A-A25B-E26D1B53240AQ34358853-D6775107-0785-43BA-99E1-15F985E40690Q34442590-48B5BE39-F923-49C2-82D8-8D878F3DC92EQ35391479-3B823664-030C-4A70-8F90-A9B4256C4166Q35500533-50116FA5-6E7B-4F7A-B3F0-C3F39931940DQ35758507-D9C79110-004E-4594-913A-F46FDB4DA53EQ36035517-DBBB5E62-602E-45C4-AD71-20DFA3167D62Q36141916-9BFDB2DB-D155-497E-B04B-75EAC82C906AQ36544455-412C382D-639E-4EEB-8A86-330D142E1C51Q36745332-D29A2987-D95A-433A-AABA-411B5DBD364FQ36751221-BCCA9A74-251E-48CA-A88D-7142A2EA6364Q37233236-DE993AD6-5D28-45F6-B63B-BA8906136749Q37327945-094E6E4D-D029-48F3-8FA7-FA5BB7A17BB6Q37500159-7AA65FAA-F191-4EF3-BBBA-41DBAB3FDBBAQ37629537-D9494410-B7BA-4C86-AAFE-A342010B1368Q37935867-0E632B06-F065-464F-B189-05D9C9CC807AQ37981504-6F6F1E88-A8F8-4601-B8F3-2CCA23310D43Q38001654-DF779A8D-D48C-46D6-85A2-F076ECFCE549Q38033600-0B02561F-CFF5-4A65-8339-3E10FA91B39AQ38117685-67DB9290-886A-46C1-BE73-362DDCA747CAQ38986891-5C0C8E0F-4AB1-4021-AFBA-3A1EDF5C5C50Q44094234-E6C431D0-E923-4250-80A6-48701081E1A5Q47097037-A6D1084D-A56E-48B4-8B64-7D6E3C1C9523Q47616387-63E905F2-86C0-4787-B6AE-A712A9A01434Q47799677-205E977C-851B-4041-A1D3-C7C68EBEB349Q51058500-8C4E0A84-34DF-4773-BB63-5F87D50BF735Q55366269-0F98B60E-65BA-41B4-B5C5-6AF7CEBE1B41
P2860
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@en
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@nl
type
label
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@en
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@nl
prefLabel
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@en
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@nl
P2860
P356
P1476
Improving outcomes for high-risk ALL: translating new discoveries into clinical care.
@en
P2093
Elizabeth A Raetz
Mignon L Loh
P2860
P304
P356
10.1002/PBC.22996
P577
2011-02-15T00:00:00Z